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Amniotic fluid embolism (AFE) remains one of the principal reported causes of direct mater-
nal mortality in high-income countries. However, obtaining robust information about the con-
dition is challenging because of its rarity and its difficulty to diagnose. This study aimed to
pool data from multiple countries in order to describe risk factors, management, and out-
comes of AFE and to explore the impact on the findings of considering United Kingdom,
international, and United States AFE case definitions.
Methods and findings
A population-based cohort and nested case-control study was conducted using the Interna-
tional Network of Obstetric Survey Systems (INOSS). Secondary data on women with AFE
(n = 99–218, depending on case definition) collected prospectively in population-based
studies conducted in Australia, France, the Netherlands, Slovakia, and the UK were pooled
along with secondary data on a sample of control women (n = 4,938) collected in Australia
and the UK. Risk factors for AFE were investigated by comparing the women with AFE in
Australia and the UK with the control women identified in these countries using logistic
regression. Factors associated with poor maternal outcomes (fatality and composite of fatal-
ity or permanent neurological injury) amongst women with AFE from each of the countries
were investigated using logistic regression or Wilcoxon rank–sum test. The estimated inci-
dence of AFE ranged from 0.8–1.8 per 100,000 maternities, and the proportion of women
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with AFE who died or had permanent neurological injury ranged from 30%–41%, depending
on the case definition. However, applying different case definitions did not materially alter
findings regarding risk factors for AFE and factors associated with poor maternal outcomes
amongst women with AFE. Using the most liberal case definition (UK) and adjusting for the
severity of presentation when appropriate, women who died were more likely than those
who survived to present with cardiac arrest (89% versus 40%, adjusted odds ratio [aOR]
10.58, 95% confidence interval [CI] 3.93–28.48, p < 0.001) and less likely to have a source
of concentrated fibrinogen (40% versus 56%, aOR 0.44, 95% CI 0.21–0.92, p = 0.029) or
platelets given (24% versus 49%, aOR 0.23, 95% CI 0.10–0.52, p < 0.001). They also had a
lower dose of tranexamic acid (median dose 0.7 g versus 2 g, p = 0.035) and were less likely
to have had an obstetrician and/or anaesthetist present at the time of the AFE (61% versus
75%, aOR 0.38, 95% CI 0.16–0.90, p = 0.027). Limitations of the study include limited statis-
tical power to examine factors associated with poor maternal outcome and the potential for
residual confounding or confounding by indication.
Conclusions
The findings of our study suggest that when an AFE is suspected, initial supportive obstetric
care is important, but having an obstetrician and/or anaesthetist present at the time of the
AFE event and use of interventions to correct coagulopathy, including the administration of
an adequate dose of tranexamic acid, may be important to improve maternal outcome.
Future research should focus on early detection of the coagulation deficiencies seen in AFE
alongside the role of tranexamic acid and other coagulopathy management strategies.
Author summary
Why was this study done?
• Amniotic fluid embolism (AFE) is a rare pregnancy complication in which amniotic
fluid or foetal material enters the woman’s blood stream and triggers a severe reaction.
• Women with AFE may collapse suddenly during or shortly after they give birth, and it
often results in the death of the mother.
• The rarity of AFE, together with the fact that it is a hard condition to diagnose and sev-
eral case definitions have been proposed, makes it difficult to obtain reliable information
about the condition.
What did the researchers do and find?
• Data on women with AFE (n = 99–218 depending on case definition) collected in five
high-income countries were studied along with data on a sample of control women
without AFE (n = 4,938) collected in two of the countries.
• Depending on the definition of AFE used, AFE was found to affect between 1 in every
125,000 to 1 in every 55,000 women giving birth, and between 30%–41% of women with
the condition died or had permanent neurological injury.
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• Applying different case definitions resulted in similar findings regarding factors associ-
ated with the occurrence of AFE and factors associated with poor maternal outcomes
amongst women with AFE.
• Amongst women with AFE, those with poor maternal outcome were less likely to have
had interventions such as platelets to correct blood clotting problems, had a lower dose
of tranexamic acid, and were less likely to have had an obstetrician and/or anaesthetist
present at the time of the AFE event.
What do these findings mean?
• Our findings suggest that having an obstetrician and/or anaesthetist present at the time
of the event and the use of interventions to correct blood clotting abnormalities, includ-
ing the administration of an adequate dose of tranexamic acid, may be important to
improve maternal outcomes in women with AFE.
Introduction
Amniotic fluid embolism (AFE), although rare—affecting an estimated 1.7 per 100,000 mater-
nities in the UK—remains one of the principal reported causes of direct maternal mortality in
high-income countries [1–5]. The condition is characterised by unexplained sudden cardiovas-
cular collapse, respiratory distress, and disseminated intravascular coagulation (DIC). Obtain-
ing robust information about risk factors, management, and outcomes of AFE is challenging
owing to the rarity of the condition, combined with the fact that clinical diagnosis of AFE is
one of exclusion and various case definitions have been proposed [1,6–8]. Previous reviews
have highlighted the lack of consistency in the factors reported to be associated with the occur-
rence of AFE and the limited evidence on factors associated with poor outcomes [2,9]. Analysis
of pooled international data, obtained using consistent methodologies with agreed definitions,
could provide more reliable information on these associated factors and hence provide the
potential to develop appropriate evidence-based preventive strategies and guide best practice.
The International Network of Obstetric Survey Systems (INOSS) is a collaboration of orga-
nisations in over 15 countries conducting prospective population-based studies of uncommon
and severe complications in pregnancy and childbirth using comparable surveillance systems
[10]. Five INOSS members in Australia, France, the Netherlands, Slovakia, and the UK have
collected data on women with AFE, and two of the INOSS members in Australia and the UK
have also collected information on a sample of control women. The aim of this study was to
pool these data in order to describe risk factors, management, and outcomes of AFE, as well as
identify whether there are specific factors that are associated with poor maternal outcomes.
We also aimed to explore the impact on the findings of considering UK, international, and US
case definitions of AFE [1,6–8].
Methods
Study design and data collection
A multicountry, population-based cohort and nested case-control study was conducted using
the INOSS. We pooled anonymous individual-level data on women with AFE that were
Risk factors, management, and outcomes of amniotic fluid embolism
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collected prospectively in five population-based studies conducted by members of INOSS in
Australia, France, the Netherlands, Slovakia, and the UK. The studies were conducted in Aus-
tralia between 1 January 2010 and 31 December 2016, using the Australasian Maternity Out-
comes Surveillance System (AMOSS) [11]; in France between 1 May 2012 and 30 November
2013, using the Épidémiologie de la Morbidité Maternelle Sévère (EPIMOMS) [12] study; in
the Netherlands between 1 September 2013 and 31 August 2016, using the Netherlands Obstet-
ric Surveillance System (NethOSS); in Slovakia between 1 January 2012 and 31 December
2016, using the Slovak Obstetric Survey System (SOSS); and in the UK between 1 February
2005 and 31 January 2018, using the UK Obstetric Surveillance System (UKOSS) [13]. Austra-
lia, Slovakia, and the UK have previously published some of their data in peer-reviewed jour-
nals [1,6,14–17]. With the exception of the French study, which was conducted in six regions
of France (Alsace, Auvergne, Basse-Normandie, Ile-de-France, Lorraine, and Rhône-Alpes)
covering one-fifth of all deliveries in the country, studies were nationwide, with nominated cli-
nicians in each maternity unit in the country contacted on a monthly basis and asked to report
all cases of AFE (see Table 1 for definitions of AFE used by participating countries). On report-
ing a case, clinicians were prompted to complete data collection forms from the woman’s med-
ical notes to confirm the diagnosis and obtain additional information on potential risk factors,
management (including coagulation and blood products, surgical interventions such as hyster-
ectomy, and the presence of medical personnel at the time of the maternal collapse), and out-
comes. In France, the completeness of case identification was checked through the review of
delivery logbooks, hospital discharge data, and laboratory files. Maternal deaths reported
through EPIMOMS were also cross-checked with maternal deaths reported to the National
Confidential Enquiries on Maternal Mortality (ENCMM). In the Netherlands, maternal deaths
from AFE reported through NethOSS were cross-checked with maternal deaths reported to
the Netherlands Audit Committee Maternal Mortality and Morbidity. In Slovakia, maternal
deaths from AFE reported through SOSS were cross-checked with mandatory reports of
maternal deaths kept by the chief of Gynecology and Obstetrics of the Ministry of Health in
Slovakia. In the UK, maternal deaths from AFE reported through UKOSS were cross-checked
with maternal deaths reported to the Centre for Maternal and Child Enquiries (CMACE) and
the National Maternal, Newborn and Infant Clinical Outcome Review Programme run by
MBBRACE-UK.
We also pooled anonymous individual-level data on a sample of control women without
AFE that were collected in Australia and the UK. In Australia, the control women were identi-
fied by AMOSS reporting clinicians as the two women delivering immediately before other
AMOSS study cases identified between January 2010 and December 2011 [18]. The AMOSS
reporting clinicians were asked to complete a data collection form for the control women that
was identical to that used to capture general non-case–specific information about all condi-
tions, including AFE, studied by AMOSS. In the UK, the control women were identified by
UKOSS reporting clinicians as the two women delivering in the same hospital immediately
before other UKOSS study cases identified at various periods between February 2005 and June
2014 [19–27]. The UKOSS reporting clinicians were asked to complete a data collection form
for the control women that was identical to that used for the particular UKOSS study cases,
with the exception of the case-specific information. Although UKOSS individually develops
data collection forms for each condition it studies, the data collection forms for the different
conditions contain common data items about women’s characteristics. The control women
were comparable in characteristic to the available national data on women giving birth in the
respective countries [28–30].
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Table 1. Case definitions of AFE.
Criteria
Definitions of AFE used by participating INOSS members
Australia (AMOSS) Either as a clinical diagnosis (acute hypotension or cardiac arrest, acute hypoxia and
coagulopathy in the absence of any other potential explanation for the symptoms and signs
observed) or as a postmortem diagnosis (presence of foetal squames/debris in the pulmonary
circulation).
France (EPIMOMS) Women with SAMM attributed to AFE by the clinicians in charge. The EPIMOMS study
used a standardised definition of SAMM that was developed through a national Delphi
formal expert consensus process, intended to characterise maternal complications with
severe health alteration and organ dysfunction. The multicriteria definition of SAMM
combined diagnoses (severe obstetric bleeding, eclampsia, severe preeclampsia, pulmonary
embolism, stroke, and psychiatric disorder), organ dysfunctions (hepatic, haematological,
respiratory, cardiovascular, renal, and neurological), and interventions (admission to
Intensive Care Unit and laparotomy after delivery).
Netherlands
(NethOSS)
Same as UK (UKOSS).
Slovakia (SOSS) Same as UK (UKOSS).








Premonitory symptoms, e.g., restlessness, numbness, agitation, tingling
Seizure
Shortness of breath
Excluding: women with maternal haemorrhage as the first presenting feature in whom there
was no evidence of early coagulopathy or cardiorespiratory compromise
OR
Women in whom the diagnosis was made at postmortem examination with the finding of
foetal squames or hair in the lungs.
Other definitions of AFE
INOSS An acute cardiorespiratory collapse within 6 hours after labour, birth, or ruptured
membranes, with no other identifiable cause, followed by acute coagulopathy in those
women who survive the initial event.
Clark and colleagues
[8]
1. Sudden onset of cardiorespiratory arrest, or both hypotension (systolic blood pressure
<90 mm Hg) and respiratory compromise (dyspnoea, cyanosis, or peripheral capillary
oxygen saturation [SpO2] <90%).
2. Documentation of overt DIC following appearance of these initial signs or symptoms,
using scoring system of Scientific and Standardization Committee on DIC of the ISTH,
modified for pregnancy.� Coagulopathy must be detected prior to loss of sufficient blood to
itself account for dilutional or shock-related consumptive coagulopathy.
3. Clinical onset during labour or within 30 minutes of delivery of placenta.
4. No fever (�38.0 ˚C) during labour.
�Scoring system of Scientific and Standardization Committee on DIC of the ISTH, modified for pregnancy:
• Platelet count: > 100,000/mL = 0, <100,000/mL = 1, <50,000/mL = 2;
• Prolonged prothrombin time or international normalized ratio: <25% increase = 0, 25%–50% increase = 1, >50%
increase = 2;
• Fibrinogen level: >200 mg/L = 0, <200 mg/L = 1.
Score� 3 is compatible with overt DIC in pregnancy
Abbreviations: AFE, amniotic fluid embolism; AMOSS, Australasian Maternity Outcomes Surveillance System;
DIC, disseminated intravascular coagulation; EPIMOMS, Épidémiologie de la Morbidité Maternelle Sévère;
INOSS, International Network of Obstetric Survey Systems; ISTH, International Society on Thrombosis and
Hemostasis; NethOSS, Netherlands Obstetric Surveillance System; SAMM, severe acute maternal morbidity; SOSS,
Slovak Obstetric Survey System; UKOSS, UK Obstetric Surveillance System.
https://doi.org/10.1371/journal.pmed.1002962.t001
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Case definition
For the purpose of this study, three case definitions of AFE were considered: 1) the UKOSS
case definition [1,6]; 2) a definition of AFE developed through a Delphi process by members
of INOSS [7], hereafter referred to as the INOSS case definition; and 3) a definition of AFE
proposed by Clark and colleagues [8], hereafter referred to as the Clark case definition (see
Table 1 for details of each of these case definitions). Because of the data available in each of the
participating INOSS countries, we had to apply the following modifications to the INOSS and
Clark criteria. Women were identified as having acute cardiorespiratory collapse, a component
of the INOSS case definition, if they had any of the following features present at or immedi-
ately preceding diagnosis defined according to usual hospital ranges: cardiac arrest, cardiac
rhythm problems, or hypotension. Women were considered as having the first criterion of the
Clark case definition (sudden onset of cardiorespiratory arrest or both hypotension and respi-
ratory compromise) if they had the following features present at or immediately preceding
diagnosis: cardiac arrest or cardiac rhythm problems or both hypotension and shortness of
breath. Because only a few women in our study had sufficient laboratory results collected to
determine if they met the second criterion of the Clark definition (overt DIC; see Table 1),
women were considered to meet this criterion or the acute coagulopathy component of the
INOSS definition if they had coagulopathy recorded as a feature present at or immediately pre-
ceding diagnosis or had the laboratory levels compatible with DIC that feature in the Clark def-
inition. Because none of the participating INOSS countries collected data on the time the
placenta was delivered, women were determined as meeting the third criterion of the Clark
case definition (clinical onset during labour or within 30 minutes of delivery of placenta) if
they had clinical onset during labour or within 60 minutes of delivery. Finally, women were
considered as meeting the fourth criterion of the Clark case definition (no fever [�38.0 ˚C]
during labour) if they had no evidence of infection recorded or had an infection that was
clearly prelabour or postevent. Recognising that we applied these modifications to the INOSS
and Clark criteria, we hereafter refer to these definitions in our study as modified INOSS and
Clark case definitions, respectively.
Statistical analysis
All analyses were prespecified as described in detail in the methods section and outlined in the
study protocol (S1 Study Protocol), with the exception of adjusting, when possible, the analysis
of maternal outcome in relation to the timing of when interventions were used for cardiac
arrest. This was performed in response to peer reviewer comments. As stated in the study pro-
tocol, we had originally planned to include AFE cases collected in New Zealand and Denmark
but did not include these cases because data sharing with INOSS members in these countries
was not possible in the timeline of this study.
Incidence rates for AFE with exact Poisson 95% confidence intervals (95% CIs) were calcu-
lated using as a denominator the available data on the number of maternities recorded region-
ally or nationally during each study period. Putative risk factors for AFE identified from the
literature were investigated by comparing the women with AFE in the UK and Australia to the
control group of women identified in these countries using unconditional logistic regression
to estimate odds ratios (ORs) and 95% CIs. A full regression model was developed by including
both explanatory and potential confounding factors in a core model if there was a pre-existing
hypothesis or evidence to indicate that they were causally related to AFE. Plausible interac-
tions, including whether there was evidence to suggest that any associations varied by country,
were assessed by the addition of interaction terms to the full model and subsequent likelihood
ratio testing. Using fractional polynomials, there was no evidence that continuous variables
Risk factors, management, and outcomes of amniotic fluid embolism
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showed evidence of departure from linearity. Continuous variables were therefore treated as
continuous linear terms when adjusting for them in the analysis but were presented as categor-
ical variables for ease of interpretation.
The pooled data on women with AFE from each of the five countries were used to describe
the management and outcomes of AFE. Factors associated with poor maternal outcomes
(fatality and composite of fatality or permanent neurological injury, including persistent vege-
tative state, anoxic/hypoxic brain injury, or cerebrovascular accident, with the composite here-
after referred to as severe outcome) amongst women with AFE from each of the countries
were investigated using unconditional logistic regression or Wilcoxon rank–sum test as appro-
priate. In all analyses, only factors that were collected in a comparable way between countries
were included. Because the proportion of missing data was low for most variables of interest
and mostly missing because of certain data items not being collected in one or more of the
countries (see table footnotes), only the observed data were analysed (complete case analysis).
All p-values were two-sided with the significance level set at<0.05, except for interaction tests,
in which the significance level was set at<0.01 to allow for multiple testing. All analyses were
performed using STATA v. 15 (StataCorp, College Station, TX, USA). This study is reported as
per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
guideline (S1 STROBE Checklist).
Sample size and power
The sample size was predetermined by the sample size of the participating countries existing
studies. Assuming putative risk factors have a prevalence of 5% or 40%, the AFE risk factor
analysis had 80% power at the 5% level of significance to detect ORs of 2.2 or greater and 1.6
or greater, respectively, using the UKOSS case definition; 2.5 or greater and 1.7 or greater,
respectively, using the modified INOSS case definition; and 2.9 or greater and 1.9 or greater,
respectively, using the modified Clark case definition. Assuming factors assessed have a preva-
lence of 5% or 40%, the analysis examining factors associated with fatality amongst AFE cases
had 80% power at the 5% significance level to detect ORs of 5.0 or greater and 2.8 or greater,
respectively, using the UKOSS case definition; 5.9 or greater and 3.1 or greater, respectively,
using the modified INOSS case definition; and 8.4 or greater and 4.5 or greater, respectively,
using the modified Clark case definition. The corresponding figures for the analysis of factors
associated with death or permanent neurological injury were an OR of 4.8 or greater and 2.6
or greater, respectively, using the UKOSS case definition; 6.1 or greater and 3.1 or greater,
respectively, using the modified INOSS case definition; and 8.4 or greater and 4.2 or greater,
respectively, using the modified Clark case definition.
Approvals
This was a secondary analysis of previously collected anonymous data. The only ethical
approval required was to export data from Australia to the UK for the analysis of this study.
Ethical approval (reference: HREC/09/CIPHS/21) was granted by the New South Wales Popu-
lation and Health Services Research Ethics Committee [31]. Data sharing agreements were
also signed with each participating institution.
Results
Table 2 shows the number and incidence of AFE by definition of AFE used and by country,
and Fig 1 illustrates the number of women meeting each case definition of AFE. The incidence
of AFE varied according to the definition of AFE applied with the overall incidence 1.8 per
100,000 maternities (95% CI 1.5–2.0) using the UKOSS case definition; 1.2 per 100,000
Risk factors, management, and outcomes of amniotic fluid embolism
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Table 2. Numbers and incidence of AFE (95% CI) per 100,000 maternities¥ by definition of AFE and by country.
Country Study Period Total No. of Maternities¥ during
Study Period
Definition Used















1,959,945 36 1.8 (1.3–2.5) 28 1.4 (0.9–2.1) 20 1.0 (0.6–1.6)
France 01/05/2012–30/
11/2013
182,309 8 4.4 (1.9–8.7) 4 2.2 (0.6–5.6) 2 1.1 (0.1–4.0)
Netherlands 01/09/2013–31/
08/2016
502 559 8 1.6 (0.7–3.1) 5 1.0 (0.3–2.3) 2 0.4 (0.05–1.4)
Slovakia 01/01/2012–31/
12/2016
276,098 5 1.8 (0.6–4.2) 3 1.1 (0.2–3.2) 3 1.1 (0.2–3.2)
UK 01/02/2005–31/
01/2018
9,986,092 161 1.6 (1.4–1.9) 103 1.0 (0.8–1.3) 72 0.7 (0.6–0.9)
TOTAL 12,404,444 218 1.8 (1.5–2.0) 143 1.2 (1.0–1.4) 99 0.8 (0.6–1.0)
¥Australia: �20 week gestation or resulting in birth of a baby weighting�400 g; France:�22 weeks gestation; Netherlands, Slovakia, and UK:�24 weeks gestation.
Abbreviations: AFE, amniotic fluid embolism; CI, confidence interval; INOSS, International Network of Obstetric Survey Systems; no., number; UKOSS, UK Obstetric
Surveillance System.
https://doi.org/10.1371/journal.pmed.1002962.t002
Fig 1. Total number of women in Australia, France, the Netherlands, Slovakia, and the UK meeting UKOSS case definition (dark blue), modified
INOSS case definition (medium blue), and modified Clark case definition (light blue) of AFE. AFE, amniotic fluid embolism; INOSS, International
Network of Obstetric Survey Systems; UKOSS, UK Obstetric Surveillance System.
https://doi.org/10.1371/journal.pmed.1002962.g001
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maternities (95% CI 1.0–1.4) using the modified INOSS case definition; and 0.8 per 100,000
maternities (95% CI 0.6–1.0) using the modified Clark case definition. A lack of evidence of
coagulopathy/DIC was the most common reason for the UKOSS cases not meeting the other
case definitions, with 43 women and 36 women not meeting the modified INOSS and Clark
case definitions, respectively, on this one criterion alone. The apparently higher incidence of
AFE in France compared to the other countries when the UKOSS case definition was used was
not evident when the modified Clark case definition was applied. Of the six women in France
who met the UKOSS but not the modified Clark case definition, two women did not meet the
modified Clark definition because it could not be determined whether they had clinical onset
during labour or within 60 minutes of delivery because of missing data; two of the women did
not meet the modified Clark definition because they did not have clinical onset during labour
or within 60 minutes of delivery, one of whom additionally had no evidence of coagulopathy/
DIC; and the remaining two women did not meet the modified Clark definition because they
did not have evidence of cardiorespiratory arrest or both hypotension and respiratory
compromise.
Risk factors
Table 3 shows the characteristics of the women in the UK and Australia with AFE according to
the UKOSS case definition compared to the control women identified in these countries. The
odds of having AFE rose significantly with increasing maternal age, showing no evidence of
departure from linearity (adjusted OR [aOR] 1.12, 95% CI 1.08–1.15, p< 0.001 for every
1-year increase in age; presented in Table 3 as a binary variable for ease of interpretation). The
odds of having AFE were also significantly raised in women who had a multiple pregnancy,
polyhydramnios, placenta praevia, placental abruption, and induction of labour using any
method. Information on prostaglandin labour induction and oxytocin use in labour was avail-
able for the women with AFE and a subset of the control women. Adjusted analysis revealed
that the odds of having AFE were significantly raised in women induced with prostaglandin
compared to those induced without prostaglandin (aOR 2.46, 95% CI 1.17–5.15, p = 0.017) but
were not significantly higher in women who had oxytocin used during labour compared to
those who laboured without oxytocin (aOR 1.31, 95% CI 0.83–2.07, p = 0.240).
Considering just the AFE cases that occurred postnatally, both instrumental vaginal birth
and cesarean section were associated with significantly raised odds of having AFE postnatally
(aOR 9.82, 95% CI 3.93–24.49, p< 0.001 and aOR 14.02, 95% CI 6.25–31.42, p< 0.001, respec-
tively). Of those who had AFE after a cesarean section, 61% (41/67) did not labour, and 81%
(54/67) had the urgency of cesarean section recorded, with cesarean performed as an emer-
gency (grade or category 1 or 2 urgency [32,33]) in 22 of the women (12 for foetal compromise,
5 for maternal compromise, 5 for other indications) and as an elective procedure (grade or
category 3 or 4 urgency [32,33]) in 32 of the women (10 for previous cesarean birth, 4 for
maternal request, 5 for abnormal presentation, and 13 for other indications). No significant
interactions were found, and the nature of the associations was unaffected by adjusting for
country.
Applying the modified INOSS or modified Clark case definition (S1 and S2 Tables) did not
change the findings, with the exceptions of gestational diabetes, placental abruption, and
instrumental vaginal birth, when the modified Clark definition was applied. Using the modi-
fied Clark case definition, women with gestational diabetes had significantly raised odds of
having AFE (aOR 2.22, 95% CI 1.00–4.91, p = 0.049), while those with placental abruption and
instrumental vaginal birth no longer had significantly higher odds of having the condition
(aOR 4.70, 95% CI 0.46–47.59, p = 0.190 and aOR 2.97, 95% CI 0.63–13.88, p = 0.167,
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Table 3. Comparison of characteristics of women with AFE according to UKOSS case definition and control women in the UK and Australia.
Number (%)a of Cases
(n = 197)
Number (%)a of Controls
(n = 4,938)
Unadjusted OR (95% CI, p-
Value)




Less than 35 112 (57) 3,884 (79) 1 1
35 or more 85 (43) 1,048 (21) 2.81 (2.10–3.76, <0.001) 2.40 (1.71–3.37,
<0.001)
Body mass index at booking (kg/m2)¥
Less than 30 143 (79) 3,677 (80) 1 1
30 or more 39 (21) 892 (20) 1.12 (0.78–1.61, 0.526) 1.05 (0.70–1.58, 0.818)
Smoking status¥
Never/ex-smoker 168 (87) 3,979 (82) 1 1
Smoked during pregnancy 26 (13) 860 (18) 0.72 (0.47–1.09, 0.119) 1.20 (0.74–1.92, 0.458)
Previous obstetric and medical history
Parity¥,b
0 77 (−40) 2,134 (43) 1 1
1 or more 117 (60) 2,797 (57) 1.16 (0.86–1.55, 0.323) 0.90 (0.64–1.26, 0.522)
Chronic hypertension¥
No 186 (95) 4,862 (99) 1 1
Yes 9 (5) 48 (1) 4.90 (2.08–10.29, <0.001) 1.10 (0.37–3.29, 0.867)
Pre-existing diabetes¥
No 194 (99) 4,860 (99) 1
Yes 2 (1) 51 (1) 0.98 (0.12–3.78, 1.000)
Current pregnancy characteristics
Multiple pregnancy
No 178 (90) 4,866 (99) 1 1
Yes 19 (10) 71 (1) 7.31 (4.07–12.59, <0.001) 6.28 (3.23–12.22,
<0.001)
Gestational diabetes¥
No 183 (93) 4,742 (97) 1 1
Yes 13 (7) 160 (3) 2.11 (1.17–3.78, 0.013) 1.44 (0.74–2.79, 0.284)
Hypertensive disorder¥
No 174 (89) 4,688 (96) 1 1
Yes 22 (11) 215 (4) 2.76 (1.73–4.39, <0.001) 1.48 (0.79–2.75, 0.217)
Polyhydramnios¥
No 188 (96) 4,866 (99) 1 1
Yes 8 (4) 32 (1) 6.47 (2.54–14.58, <0.001) 5.04 (1.90–13.36,
0.001)
Placenta praevia¥
No 180 (92) 4,878 (99) 1 1
Yes 16 (8) 31 (1) 13.96 (7.00–26.88, <0.001) 13.26 (6.35–27.69,
<0.001)
Placental abruption¥
No 191 (97) 4,893 (100) 1 1
Yes 5 (3) 8 (0.2) 15.98 (4.07–56.01, <0.001) 14.14 (3.52–56.86,
<0.001)
Induction of labour using any method¥,c
No 117 (59) 3,752 (76) 1 1
Yes 80 (41) 1,179 (24) 2.18 (1.63–2.91, <0.001) 2.37 (1.68–3.34,
<0.001)
(Continued)
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respectively), noting the more limited power of the analysis and the borderline significance of
the gestational diabetes finding.
Presentation, management, and outcomes of AFE
The proportion of women with AFE who died and the proportion who had a severe outcome
(died or had permanent neurological injury) varied slightly according to the definition of AFE
used: using the UKOSS case definition, 21% (45/216, 95% CI 16%–27%) of all women with
AFE died, and 30% (57/193, 95% CI 23%–37%) had a severe outcome; using the modified
INOSS case definition, 30% (42/142, 95% CI 22%–38%) of all women with AFE died, and 41%
(51/125, 95% CI 32%–50%) had a severe outcome; and using the modified Clark case defini-
tion, 24% (24/99, 95% CI 16%–34%) of all women with AFE died, and 39% (33/84, 95% CI
29%–51%) had a severe outcome.
Table 4 shows the presentation and haematological parameters of women with AFE accord-
ing to the UKOSS case definition by outcome. Applying the UKOSS case definition, women
with AFE who had a severe outcome were more likely than those who did not have a severe
outcome to present with cardiac arrest. This finding was also apparent when the analysis was
limited to comparing women with AFE who died with those who survived (Table 4) and when
the modified INOSS or modified Clark case definition was applied (S3 and S4 Tables). In the
adjusted analysis, no other significant difference in presentation and haematological parame-
ters were apparent between the women who had poor outcome and those who did not, except
when the modified INOSS case definition was applied and the analysis limited to comparing
women who died to those who survived. When the modified INOSS case definition was used,
women who died were also found to be less likely than those who survived to have coagulopa-
thy noted at presentation (aOR 0.16, 95% CI 0.04–0.64, p = 0.009), having adjusted for other
Table 3. (Continued)
Number (%)a of Cases
(n = 197)
Number (%)a of Controls
(n = 4,938)
Unadjusted OR (95% CI, p-
Value)
aOR (95% CI, p-
Value)Ϯ
Gestational age at delivery (weeks)¥,d
Term (37–41) 160 (82) 4,412 (90) 1 1
Preterm (<37) 31 (16) 369 (8) 2.32 (1.55–3.45, <0.001) 1.22 (0.72–2.09, 0.462)
Post-term (42 or more) 3 (2) 136 (3) 0.61 (0.19–1.93, 0.399) 0.58 (0.18–1.89, 0.366)
Macrosomia (birthweight of 4,000 g or
more)¥,d
No 169 (90) 4,359 (89) 1 1
Yes 19 (10) 558 (11) 0.88 (0.54–1.42, 0.598) 0.87 (0.51–1.48, 0.605)
aPercentage of those with complete data.
ϮAdjusted for all variables in table apart from pre-existing diabetes.
bAustralia (AMOSS): number of previous pregnancies�20 week gestation or resulting in birth of a baby weighting�400g; UK (UKOSS): number of completed
pregnancies �24 week gestation.
cIn Australia, data on induction of labour only collected for women who laboured. Women who did not labour in Australia assumed to have had no induction of labour.
dExcludes 11 women who had pregnancies ending before 24 week gestation
¥Missing data: maternal age n = 6, 0.1%; body mass index n = 384, 7.5%; smoking status n = 102, 2.0%; parity n = 10, 0.2%; chronic hypertension n = 30, 0.6%; pre-
existing diabetes n = 28, 0.5%; multiple pregnancy n = 1, 0.02%; gestational diabetes n = 37, 0.7%; hypertensive disorder n = 36, 0.7%; polyhydramnios n = 41, 0.8%;
placenta praevia n = 30, 0.6%; placental abruption n = 38, 0.7%; labour induced n = 7, 0.1%; gestational age at delivery n = 13, 0.3%; macrosomia n = 19, 0.4%.
Bold text indicates statistically significant findings at the 5% level.
Abbreviations: AFE, amniotic fluid embolism; AMOSS, Australasian Maternity Outcomes Surveillance System; aOR, adjusted OR; CI, confidence interval; OR, odds
ratio; UKOSS, UK Obstetric Surveillance System.
https://doi.org/10.1371/journal.pmed.1002962.t003
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Table 4. Using the UKOSS case definition, comparison of the presentation and haematological parameters of AFE cases who died to those who survived and of AFE
cases that had severe outcome to those that did not have severe outcome.
No. (%)a of
Cases that











No. (%)a of Cases
that Had Severe
Outcomeb (n = 57)c
No. (%)a of Cases that
Did Not Have Severe











23 (55) 77 (47) 1 29 (55) 64 (48) 1
Postdelivery 19 (45) 88 (53) 0.72 (0.37–1.43,
0.350)






15 (33) 62 (36) 0.88 (0.44–1.76,
0.716)
20 (35) 49 (36) 0.96 (0.50–1.83,
0.901)














9 (24) 45 (27) 0.83 (0.36–1.88,
0.652)
11 (23) 35 (26) 0.83 (0.38–1.81,
0.643)
Coagulopathy 27 (60) 108 (63) 0.87 (0.45–1.71,
0.697)
35 (61) 78 (57) 1.18 (0.63–2.23,
0.603)










31 (69) 118 (69) 0.99 (0.49–2.02,
0.988)




21 (51) 69 (43) 1.38 (0.70–2.75,
0.354)
26 (51) 52 (39) 1.60 (0.83–3.07,
0.157)
Seizures¥ 7 (16) 24 (14) 1.14 (0.45–2.84,
0.786)




14 (32) 73 (44) 0.59 (0.29–1.20,
0.148)






10 (29) 61 (38) 1 13 (28) 49 (39) 1 1
50,000–100,000 11 (31) 65 (40) 1.03 (0.41–2.60),
0.946




Less than 50,000 14 (40) 35 (22) 2.44 (0.98–6.07),
0.055





<25% increase 2 (25) 13 (28) 1 2 (20) 10 (40) 1
25%–50%
increase
1 (13) 10 (21) 0.66 (0.01–14.43,
1.000)
2 (20) 7 (28) 1.40 (0.08–23.88,
1.000)
>50% increase 5 (63) 24 (51) 1.35 (0.19–16.00,
1.000)




2 or more 0 (0) 12 (21) 1 2 (15) 7 (23) 1
(Continued)
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factors that were significant in the unadjusted model, including cardiac arrest at presentation
(S3 Table). Considering just the women with AFE according to the UKOSS case definition
who did not present with cardiac arrest, 47% (48/103) presented at or before delivery, with
42% (45/108) noted to have acute fatal compromise at presentation, 20% (21/106) noted to
have cardiac rhythm problems at presentation, 60% (65/108) noted to have coagulopathy at
presentation, 77% (83/108) noted to have hypotension at presentation, 67% (72/108) noted to
have maternal haemorrhage at presentation, 47% (49/104) noted to have premonitory symp-
toms at presentation, 14% (15/106) noted to have seizures at presentation, and 56% (59/106)
noted to have shortness of breath at presentation.
In terms of sociodemographic, previous obstetric, medical history, and current pregnancy
characteristics, women with AFE according to the UKOSS case definition who had a severe
outcome only differed from those who did not have a severe outcome in that they were more
likely to be multiparous (OR 2.00, 95% CI 1.01–3.95, p = 0.047, S5 Table). However, this asso-
ciation was no longer statistically significant having adjusted for cardiac arrest at presentation
as a marker of the severity of presentation (aOR 1.91, 95% CI 0.89–4.08, p = 0.097). No signifi-
cant differences in characteristic were apparent when the analysis was limited to comparing
women who died to those who survived (S5 Table). In addition, no significant differences in
characteristic were apparent when the modified INOSS or Clark case definition was applied
(S6 and S7 Tables).
In terms of management and applying the UKOSS case definition, women who had a severe
outcome were less likely than those who did not have a severe outcome to receive a source of
concentrated fibrinogen or platelets, having adjusted for cardiac arrest at presentation
(Table 5, Fig 2A). They were also less likely to have an obstetrician and/or anaesthetist present
at the time of the AFE event, having adjusted for cardiac arrest at presentation. Of the women















No. (%)a of Cases
that Had Severe
Outcomeb (n = 57)c
No. (%)a of Cases that
Did Not Have Severe







Less than 2 8 (100) 46 (79) 2.74 (0.38–
infinity, 0.362)
11 (85) 24 (77) 1.59 (0.24–18.11,
0.925)
aPercentage of those with complete data.
bDied or had permanent neurological injury.
cData on maternal morbidity only collected from 2014 in Australia.
ϮAdjusted for factors that were significant (p< 0.05) in unadjusted model.
‡Features at presentation are not mutually exclusive,
¥Missing data/data not collected: when AFE occurred n = 9, 4.2% in died versus survived analysis and n = 8, 4.1% in severe outcome versus no severe outcome analysis;
cardiac rhythm problems n = 13, 6.0% in died versus survived analysis and n = 12, 6.2% in severe outcome versus no severe outcome analysis (not collected in France);
hypotension n = 1, 0.5%; premonitory symptoms n = 15, 6.9% in died versus survived analysis and n = 10, 5.2% in severe outcome versus no severe outcome analysis
(not collected in France); seizures n = 4, 1.9% in died versus survived analysis and n = 2, 1.0% in severe outcome versus no severe outcome analysis; shortness of breath
n = 6, 2.8% in died versus survived analysis and n = 2, 1.0% in severe outcome versus no severe outcome analysis; platelet count n = 20, 9.3% in died versus survived
analysis and n = 19, 9.8% in severe outcome versus no severe outcome analysis; INR n = 161, 74.5% in died versus survived analysis and n = 158, 81.9% in severe
outcome versus no severe outcome analysis (not collected in the UK before February 2015 and not collected in France); fibrinogen n = 150, 69.4% in died versus
survived analysis and n = 149, 77.2% in severe outcome versus no severe outcome analysis (not collected in the UK before February 2015).
Bold text indicates statistically significant findings at the 5% level.
Abbreviations: AFE, amniotic fluid embolism; aOR, adjusted OR; CI, confidence interval; INR, International Normalized Ratio; OR, odds ratio; UKOSS, UK Obstetric
Surveillance System.
https://doi.org/10.1371/journal.pmed.1002962.t004
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Table 5. Using the UKOSS case definition, comparison of the management of AFE cases who died to those who survived and of AFE cases that had severe outcome
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who had a severe outcome also had a shorter interval between the AFE event and when the
hysterectomy was performed (median interval 78 minutes, IQR 55–205 minutes) compared to
those who did not have a severe outcome (median interval 213 minutes, IQR 121–299 min-
utes). Every minute increase in interval between the AFE event and when the hysterectomy
was performed was associated with a 0.6% reduction in the odds of having a severe outcome
(OR 0.994, 95% CI 0.988–1.000, p = 0.042). However, after adjusting for cardiac arrest at pre-
sentation, this association was no longer statistically significant (aOR 0.996, 95% CI 1.000–
1.002, p = 0.157). No other significant differences in management, including in terms of
median units of blood products received or timings of when interventions were used, were
found between these groups of women. When the analysis was limited to comparing women
with AFE who died with those who survived, the same findings were found with respect to
fibrinogen, platelets, presence of an obstetrician and/or anaesthetist (Table 5, Fig 2D), and the
timing of when hysterectomy was performed (median interval 58 minutes, IQR 28–163 min-
utes versus 175 minutes, IQR 95–270 minutes, aOR 1.000, 95% CI 1.000–1.000, p = 0.747 for




















No. (%)a of Cases











anaesthetist present at time
of event¥













anaesthetist present at time
of event or arrived within 5
minutes¥
























aPercentage of those with complete data.
bDied or had permanent neurological injury.
cData on maternal morbidity only collected from 2014 in Australia.
ϮAdjusted for cardiac arrest at presentation.
¥Missing data/data not collected: whole blood or packed red cells n = 2, 0.9% in died versus survived and n = 2, 1.0% in severe outcome versus no severe outcome
analysis; platelets n = 1, 0.5%; factor VIIa n = 3, 1.4% in died versus survived and n = 2, 1.0% in severe outcome versus no severe outcome analysis; tranexamic acid
n = 4, 1.9% in died versus survived and n = 2, 1.0% in severe outcome versus no severe outcome analysis; intrauterine balloons n = 4, 1.9% in died versus survived and
n = 2, 1.0% in severe outcome versus no severe outcome analysis; intra-abdominal packing n = 4, 1.9% in died versus survived and n = 2, 1.0% in severe outcome versus
no severe outcome analysis; intrauterine packing n = 12, 5.5% in died versus survived and n = 10, 5.2% in severe outcome versus no severe outcome analysis (not
collected in France); B-lynch or other brace suture n = 4, 1.9% in died versus survived and n = 2, 1.0% in severe outcome versus no severe outcome analysis; vessel
ligation n = 4, 1.9% in died versus survived and n = 2, 1.0% in severe outcome versus no severe outcome analysis; embolisation n = 12, 5.5% in died versus survived and
n = 10, 5.2% in severe outcome versus no severe outcome analysis (not collected in France); obstetrician and/or anaesthetist present at time of event n = 28, 12.9% in
died versus survived and n = 26, 13.5% in severe outcome versus no severe outcome analysis (not collected in France); obstetrician and/or anaesthetist present at time of
event or arrived within 5 minutes n = 23, 10.6% in died versus survived and n = 22, 11.4% in severe outcome versus no severe outcome analysis (not collected in France);
plasma/blood exchange n = 12, 5.5% in died versus survived and n = 11, 5.7% in severe outcome versus no severe outcome analysis (not collected in France).
Bold text indicates statistically significant findings at the 5% level.
Abbreviations: AFE, amniotic fluid embolism; aOR, adjusted OR; CI, confidence interval; OR, odds ratio; UKOSS, UK Obstetric Surveillance System.
https://doi.org/10.1371/journal.pmed.1002962.t005
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Additionally, of those given tranexamic acid, the women who died received a lower dose of
this intervention compared to those who survived (median dose 0.7 g, IQR 0.4–1 g versus 2 g,
IQR 1–2, p = 0.035). Few women received a source of concentrated fibrinogen in addition to
platelets and tranexamic acid (S1 Fig).
When the modified INOSS case definition was used, women who had a severe outcome
were found to be less likely than those who did not have a severe outcome to receive whole or
packed red cells, a source of concentrated fibrinogen, fresh-frozen plasma, platelets, or tra-
nexamic acid, even having adjusted for cardiac arrest at presentation (S8 Table, Fig 2B). Of the
women who received whole or packed red cells or a source of concentrated fibrinogen or had a
hysterectomy and had data available on when these interventions were used, those who had a
Fig 2. Comparison of the management of AFE cases that had severe outcome to those that did not have severe outcome using (A) UKOSS, (B)
modified INOSS, and (C) modified Clark case definition and comparison of the management of AFE cases who died to those who survived using
(D) UKOSS, (E) modified INOSS, and (F) modified Clark case definition. § = adjusted for cardiac arrest at presentation. � = died or had permanent
neurological injury. AFE, amniotic fluid embolism; INOSS, International Network of Obstetric Survey Systems; UKOSS, UK Obstetric Surveillance
System.
https://doi.org/10.1371/journal.pmed.1002962.g002
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severe outcome also had a shorter interval between the AFE event and when the red cells were
given (median interval 24 minutes, IQR 15–43 minutes versus 49 minutes, IQR 40–73 min-
utes, p = 0.035) or the source of concentrated fibrinogen was given (median interval 64 min-
utes, IQR 64–112 minutes versus 120 minutes, IQR 75–190 minutes, p = 0.044) or the
hysterectomy was performed (median interval 78 minutes, IQR 55–205 versus 200 minutes,
IQR 121–270 minutes, p = 0.023). However, these findings regarding intervention timings are
based on low numbers of women, and the low number of outcome events in these analyses
precluded adjustment for cardiac arrest at presentation, with the exception of the analysis of
severe outcome in relation to interval between the AFE event and when the hysterectomy was
performed. Having adjusted for cardiac arrest at presentation, this interval was not signifi-
cantly different between the women who had and did not have a severe outcome (aOR 0.994
per minute increase in interval, 95% CI 0.988–1.001, p = 0.097). Limiting the analysis to com-
paring women with AFE who died to those who survived, the same findings were found (S8
Table, Fig 2E) except with respect to timing of when red blood cells or fibrinogen was given,
which were not significantly different. The dose of tranexamic acid given was also found to be
lower in women who died compared to those that survived (median dose 0.7 g, IQR 0.4–1 g
versus 2 g, IQR 1–2, p = 0.0435).
Applying the modified Clark case definition, women who had a severe outcome were less
likely than those who did not have a severe outcome to receive a source of concentrated fibrin-
ogen, fresh-frozen plasma, or platelets and were less likely to have an intrauterine balloon
used, having adjusted for cardiac arrest at presentation (S9 Table, Fig 2C). Of the women who
received a source of concentrated fibrinogen or had tranexamic acid given and had data avail-
able on when these interventions were used, those who had a severe outcome also had a shorter
interval between the AFE event and when the source of concentrated fibrinogen was given
(median interval 64 minutes, IQR 40–88 minutes versus 113 minutes, IQR 75–158 minutes,
p = 0.025) or the tranexamic acid was given (median interval 15 minutes, IQR 14–42 minutes
versus 66 minutes, IQR 51–95 minutes, p = 0.018). However, these findings regarding inter-
vention timings are again based on low numbers of women, and the low number of outcome
events in these analyses precluded adjustment for cardiac arrest at presentation. When the
analysis was limited to comparing women with AFE who died to those who survived, the
women who died were less likely to have had platelets given or an intrauterine balloon used
and were less likely to have had an obstetrician and/or anaesthetist present at the time of the
AFE event, even having adjusted for cardiac arrest at presentation (S9 Table, Fig 2F). No other
significant differences in management were apparent.
Discussion
Main findings
Applying different case definitions changed the estimated incidence of AFE and the estimated
proportion of women with AFE who experienced poor outcomes but did not materially alter
findings regarding factors associated with the occurrence of AFE and factors associated with
poor maternal outcomes amongst women with AFE. Older maternal age, multiple pregnancy,
polyhydramnios, placenta praevia, and induction of labour were consistently associated with
the occurrence of AFE, whichever case definition was used. Additionally, giving birth by
cesarean section was consistently associated with postnatal occurrence of AFE. There was also
evidence that placental abruption and instrumental vaginal birth are risk factors for the condi-
tion, although these associations did not reach statistical significance when the modified Clark
case definition was used, noting the more limited power of the analysis. Among women with
AFE, irrespective of which case definition was used, there was evidence that those with poor
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maternal outcome were more likely to present with cardiac arrest and less likely to have plate-
lets or a source of concentrated fibrinogen given, having taken into account the severity of pre-
sentation. There was also some evidence, when two out of the three case definitions were
applied and the severity of presentation adjusted for when possible, that those with poor
maternal outcome were less likely to have received fresh-frozen plasma, had a lower dose of
tranexamic acid, and were less likely to have had an obstetrician and/or anaesthetist present at
the time of the AFE event. Having adjusted for the severity of presentation, evidence of an
association between poor maternal outcome and less use of whole or packed red cells, tranexa-
mic acid, and intrauterine balloons only reached statistical significance when one of the three
case definitions were applied. There was also some evidence that those with poor maternal out-
come had a shorter interval between the AFE event and when certain coagulation or blood
products were used, but it is important to highlight that it was not possible to adjust these find-
ings for the severity of presentation.
Strengths and limitations
Major strengths of this study are its multicountry population-based design with data obtained
using comparable methodologies with agreed definitions and cross-checking against case cri-
teria. In conditions such as AFE, where the rarity and rapidity of onset of the condition make
randomised trials almost impossible, such international population-based studies provide the
most robust level of evidence available. The UK AFE data up to January 2014 have previously
been published, but this study adds data from a further four countries and includes UK data
collected up to January 2018. It also adds to previous research in this field by exploring the
impact of using different case definitions.
Although our study represents one of the largest studies of AFE using published case crite-
ria, the number of women with a poor outcome was still relatively small. This was particularly
so when the modified Clark case definition was applied, limiting the power of this analysis
and the ability to adjust for cardiac arrest as a marker of the severity of presentation in some
of the analyses. It should also be highlighted that even when the analysis was adjusted for
cardiac arrest, the majority of women who experienced a poor outcome presented with
this feature. Relying on voluntary reporting of cases, there is also a possibility that we have
underascertained cases or ascertained only the more severe cases. However, we feel that sig-
nificant underreporting is unlikely to have occurred because all of the participating countries
used an active surveillance system to ascertain cases, with several reporting clinicians in each
hospital. In addition, in France, the completeness of case identification was checked through
the review of delivery logbooks, hospital discharge data, and laboratory files. Furthermore,
most of the countries were able to cross-check their maternal deaths with another data
source, as detailed in the methods. Although mortality cases were confirmed with national
registry data, we recognise that retrospective review of mortality cases may falsely include
cases defined as AFE as well as falsely exclude cases. However, all cases included in our study
met the case definitions of AFE detailed in the methods. There nevertheless remains a small
possibility that some fatal cases may have been excluded by national mortality review
committees.
When studying risk factors for AFE and factors associated with poor maternal outcomes in
cases of AFE, we were not able to investigate the role of factors not collected in a comparable
way between countries, most notably ethnicity and socioeconomic status. Nevertheless, we
were still able to perform a detailed assessment of risk factors for AFE and investigate the asso-
ciation between a wide range of factors and maternal outcome. However, like other observa-
tional studies, we cannot rule out the possibility of residual confounding or confounding by
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indication. The study used data from high-income countries, and therefore, the results are
likely to be only generalizable to countries with similar resource settings.
Interpretation
Of the women in our study who had AFE according to the UKOSS case definition, around
two-thirds had AFE according to the modified INOSS case definition, and less than half had
AFE according to the modified Clark case definition. A lack of evidence of coagulopathy/DIC
was the most common reason for the UKOSS cases not meeting the other case definitions. As
recognised by those who proposed the Clark case definition, while their criteria may result in a
‘cleaner’ set of cases for research purposes, it may exclude atypical cases [34]. Our study sug-
gests that while the use of different case definitions affects the estimated incidence of AFE and
the estimated proportion of women with AFE who experience poor outcome, it has little
impact on risk factor findings or the identification of factors associated with poor maternal
outcome.
In previous research, older maternal age and induction of labour are the only factors that
have been identified as being consistently associated with the occurrence of AFE across five
countries, although the associations did not reach statistical significance in one country [9].
The limited studies that have assessed placental abnormalities as a risk factor also suggest that
placenta praevia and placental abruption are associated with the occurrence of AFE, and there
is some evidence that instrumental vaginal and cesarean birth are risk factors [2,9,35]. Obtain-
ing reliable information on factors associated with AFE has previously been hampered by not
only the rarity and the difficulty in defining the condition but also the lack of consistency in
the methodology used by studies. Previous data have also frequently been limited by a lack of
information on the timing of AFE in relation to giving birth, resulting in uncertainty regarding
whether factors such as instrumental or cesarean birth are a consequence or a cause of AFE.
As well as having information on timing, our study represents, to the best of our knowledge,
the first study to have pooled population-based international data on AFE obtained using con-
sistent methodologies with agreed definitions and cross-checking against case criteria. It thus
is able to provide a clearer more robust picture of the factors associated with the occurrence of
AFE, although we cannot rule out the possibility of residual confounding or confounding by
indication.
Limited studies have examined factors associated with severe outcomes amongst women
with AFE. A study of 227 cases ascertained from a coded national hospital admissions database
and a study of just 20 cases ascertained from a regional database with additional criteria to
exclude false positive cases both found no significant association between various sociodemo-
graphic or obstetric-related characteristics and fatality [9,36]. A study that reviewed 44 case
reports of AFE found that treatment with factor VIIa was associated with an increased risk of
death or permanent disability, while a recent study that reviewed 177 case reports of AFE only
found a significant association between oxytocin use during labour and fatality amongst typi-
cal cases of AFE defined as having the classical triad of symptoms (cardiac arrest/cardiovascu-
lar collapse, respiratory failure, coagulopathy) [37,38]. Another study of 180 cases identified
from a coded hospital admissions population database found a crude association between
induction of labour and fatality [9]. More recently, a study of 54 cases of AFE with coagulopa-
thy reported that transfusion with a fresh-frozen plasma/red blood cell ratio of 1 or more was
associated with higher survival rates [39]. Based on an analysis of the first 120 cases in the UK,
included within the cases in this study, we previously reported that women who died or had
permanent neurological injury were more likely to present with cardiac arrest, be from black
or other minority ethnic groups, have a hysterectomy, had a shorter time interval between the
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AFE event and when the hysterectomy was performed, and were less likely to receive cryopre-
cipitate [1].
The present study was able to investigate the association between a wide range of factors
and poor maternal outcome, adjusting this time for the severity of presentation when appro-
priate. The slight variation in findings when the different case definitions were applied is likely
due to varying statistical power between the analyses. Also of note, when a significant associa-
tion was found with one case definition but not another, the estimated measures of association
were in the same direction and usually of a similar magnitude. Our findings may reflect a lack
of time in the sickest of women to give coagulation and blood products or a lack of time to
give enough of a product in the case of tranexamic acid. However, they could also indicate that
better correction of coagulopathy through the use of coagulation and blood products in suffi-
cient doses could improve maternal outcome. Potential harm from tranexamic acid is thought
to be low, with the recent Woman trial finding that 1 g of intravenous tranexamic acid (with a
second dose of 1 g if bleeding continued after 30 minutes or restarted within 24 hours of the
first dose) reduces death due to bleeding in women with postpartum haemorrhage with no evi-
dence of adverse effects [40]. Platelets, fresh-frozen plasma, and cryoprecipitate, on the other
hand, have been associated with a number of adverse effects, including transfusion-transmit-
ted infections, transfusion-related acute lung injury, and allergic/anaphylactic reactions
[41,42]. However, the consideration of side effects becomes relative in the context of poten-
tially life-saving therapy. Our data also suggest that having an obstetrician and/or anaesthetic
present at the time of the AFE may improve maternal outcome.
Conclusions
While the use of different case definitions of AFE influences incidence estimates and the esti-
mated proportion of women with AFE who experience poor outcomes, it has little impact on
risk factor findings or the identification of factors associated with poor maternal outcome.
This study suggests that when an AFE is suspected, initial supportive obstetric care is impor-
tant, but having an obstetrician and/or anaesthetist present at the time of the AFE event and
use of interventions to correct coagulopathy, including the administration of an adequate dose
of tranexamic acid, may be important to improve maternal outcome. Future research should
focus on early detection of the coagulation deficiencies seen in AFE alongside the role of tra-
nexamic acid and other coagulopathy management strategies.
Supporting information
S1 Fig. Using UKOSS case definition, number of women with AFE given a source of con-
centrated fibrinogen, platelets, and/or tranexamic acid by whether they died or survived.




S1 STROBE Checklist. STROBE, strengthening the reporting of observational studies in
epidemiology.
(DOCX)
S1 Table. Comparison of characteristics of women with AFE according to modified INOSS
case definition and control women in the UK and Australia. AFE, amniotic fluid embolism.
(DOCX)
Risk factors, management, and outcomes of amniotic fluid embolism
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002962 November 12, 2019 20 / 24
S2 Table. Comparison of characteristics of women with AFE according to modified Clark
case definition and control women in the UK and Australia. AFE, amniotic fluid embolism.
(DOCX)
S3 Table. Using the modified INOSS case definition, comparison of the presentation and
haematological parameters of AFE cases who died to those who survived and of AFE cases
that had severe outcome to those that did not have severe outcome. AFE, amniotic fluid
embolism; INOSS, International Network of Obstetric Survey Systems.
(DOCX)
S4 Table. Using the modified Clark case definition, comparison of the presentation and
haematological parameters of AFE cases who died to those who survived and of AFE cases
that had severe outcome to those that did not have severe outcome. AFE, amniotic fluid
embolism.
(DOCX)
S5 Table. Using the UKOSS case definition, comparison of sociodemographic, previous
obstetric and medical history, and current pregnancy characteristics of AFE cases that
died to those who survived and of AFE cases that had severe outcome compared to those
that did not have severe outcome. AFE, amniotic fluid embolism; UKOSS, UK Obstetric Sur-
veillance System.
(DOCX)
S6 Table. Using the modified INOSS case definition, comparison of sociodemographic,
previous obstetric and medical history, and current pregnancy characteristics of AFE cases
that died to those who survived and of AFE cases that had severe outcome compared to
those that did not have severe outcome. AFE, amniotic fluid embolism; INOSS, International
Network of Obstetric Survey Systems.
(DOCX)
S7 Table. Using the modified Clark case definition, comparison of sociodemographic, pre-
vious obstetric and medical history, and current pregnancy characteristics of AFE cases
that died to those who survived and of AFE cases that had severe outcome compared to
those that did not have severe outcome. AFE, amniotic fluid embolism.
(DOCX)
S8 Table. Using the modified INOSS case definition, comparison of the management of
AFE cases who died to those who survived and of AFE cases that had severe outcome to
those that did not have severe outcome. AFE, amniotic fluid embolism; INOSS, International
Network of Obstetric Survey Systems.
(DOCX)
S9 Table. Using the modified Clark case definition, comparison of the management of
AFE cases who died to those who survived and of AFE cases that had severe outcome to
those that did not have severe outcome. AFE, amniotic fluid embolism.
(DOCX)
Acknowledgments
We would like to acknowledge the support of participating maternity units and AMOSS,
NethOSS, SOSS, and UKOSS data collectors. We would also like to acknowledge all the EPI-
MOMS obstetricians, midwives, and anaesthetists who contributed to case identification and
Risk factors, management, and outcomes of amniotic fluid embolism
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002962 November 12, 2019 21 / 24
documentation in their hospitals and research assistants who collected the data, as well as
members of the EPIMOMS Study Group.
Author Contributions
Conceptualization: Kathryn E. Fitzpatrick, Marian Knight.
Data curation: Kathryn E. Fitzpatrick, Thomas van den Akker, Kitty W. M. Bloemenkamp,
Catherine Deneux-Tharaux, Alexandra Kristufkova, Zhuoyang Li, Timme P. Schaap, Eliza-
beth A. Sullivan, Marian Knight.
Formal analysis: Kathryn E. Fitzpatrick.
Funding acquisition: Kathryn E. Fitzpatrick, Kitty W. M. Bloemenkamp, Catherine Deneux-
Tharaux, Elizabeth A. Sullivan, Derek Tuffnell, Marian Knight.
Investigation: Kathryn E. Fitzpatrick.
Methodology: Kathryn E. Fitzpatrick, Kitty W. M. Bloemenkamp, Catherine Deneux-Thar-
aux, Elizabeth A. Sullivan, Derek Tuffnell, Marian Knight.
Project administration: Kathryn E. Fitzpatrick.
Supervision: Marian Knight.
Validation: Kathryn E. Fitzpatrick, Thomas van den Akker, Kitty W. M. Bloemenkamp, Cath-
erine Deneux-Tharaux, Alexandra Kristufkova, Zhuoyang Li, Timme P. Schaap, Elizabeth
A. Sullivan, Marian Knight.
Writing – original draft: Kathryn E. Fitzpatrick.
Writing – review & editing: Thomas van den Akker, Kitty W. M. Bloemenkamp, Catherine
Deneux-Tharaux, Alexandra Kristufkova, Zhuoyang Li, Timme P. Schaap, Elizabeth A. Sul-
livan, Derek Tuffnell, Marian Knight.
References
1. Fitzpatrick KE, Tuffnell D, Kurinczuk JJ, Knight M. Incidence, risk factors, management and outcomes
of amniotic-fluid embolism: a population-based cohort and nested case-control study. BJOG. 2016; 123
(1):100–9. Epub 2015 Feb 12. https://doi.org/10.1111/1471-0528.13300 PMID: 25683758.
2. Conde-Agudelo A, Romero R. Amniotic fluid embolism: an evidence-based review. Am J Obstet Gyne-
col. 2009; 201(5):445 e1–13. https://doi.org/10.1016/j.ajog.2009.04.052 PMID: 19879393.
3. Knight M, Nair M, Tuffnell D, Shakespeare J, Kenyon S, Kurinczuk JJ, et al. Saving Lives, Improving
Mothers’ Care—Lessons learned to inform maternity care from the UK and Ireland Confidential
Enquires into Maternal Deaths and Morbidity 2013–15. Oxford: National Perinatal Epidemiology Unit,
University of Oxford; 2017.
4. Australian Institute of Health and Welfare. Maternal deaths in Australia 2012–2014. PER 92. Canberra:
AIHW; 017.
5. Bonnet MP, Zlotnik D, Saucedo M, Chassard D, Bouvier-Colle MH, Deneux-Tharaux C, et al. Maternal
Death Due to Amniotic Fluid Embolism: A National Study in France. Anesth Analg. 2018; 126(1):175–
82. https://doi.org/10.1213/ANE.0000000000002511 PMID: 28961562.
6. Knight M, Tuffnell D, Brocklehurst P, Spark P, Kurinczuk JJ, System UKOS. Incidence and risk factors
for amniotic-fluid embolism. Obstet Gynecol. 2010; 115(5):910–7. https://doi.org/10.1097/AOG.
0b013e3181d9f629 PMID: 20410762.
7. Schaap T, Bloemenkamp K, Deneux-Tharaux C, Knight M, Langhoff-Roos J, Sullivan E, et al. Defining
definitions: a Delphi study to develop a core outcome set for conditions of severe maternal morbidity.
BJOG. 2019; 126(3):394–401. Epub 2017 Aug 24. https://doi.org/10.1111/1471-0528.14833 PMID:
28755459.
Risk factors, management, and outcomes of amniotic fluid embolism
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002962 November 12, 2019 22 / 24
8. Clark SL, Romero R, Dildy GA, Callaghan WM, Smiley RM, Bracey AW, et al. Proposed diagnostic cri-
teria for the case definition of amniotic fluid embolism in research studies. Am J Obstet Gynecol. 2016;
215(4):408–12. https://doi.org/10.1016/j.ajog.2016.06.037 PMID: 27372270.
9. Knight M, Berg C, Brocklehurst P, Kramer M, Lewis G, Oats J, et al. Amniotic fluid embolism incidence,
risk factors and outcomes: a review and recommendations. BMC Pregnancy Childbirth. 2012; 12:7.
https://doi.org/10.1186/1471-2393-12-7 PMID: 22325370.
10. Knight M, Inoss. The International Network of Obstetric Survey Systems (INOSS): benefits of multi-
country studies of severe and uncommon maternal morbidities. Acta Obstet Gynecol Scand. 2014;
93(2):127–31. https://doi.org/10.1111/aogs.12316 PMID: 24382256.
11. Halliday LE, Peek MJ, Ellwood DA, Homer C, Knight M, McLintock C, et al. The Australasian Maternity
Outcomes Surveillance System: an evaluation of stakeholder engagement, usefulness, simplicity,
acceptability, data quality and stability. Aust N Z J Obstet Gynaecol. 2013; 53(2):152–7. Epub 2012 Dec
6. https://doi.org/10.1111/ajo.12020 PMID: 23216366.
12. Deneux-Tharaux C, Bouvier-Colle MH, EPIMOMS study group. Severe acute maternal morbidity in
France: the epimoms population-based study. Am J Obstet Gynecol 2017; 216(1):S345–S6.
13. Knight M, Kurinczuk JJ, Tuffnell D, Brocklehurst P. The UK Obstetric Surveillance System for rare disor-
ders of pregnancy. BJOG. 2005; 112(3):263–5. https://doi.org/10.1111/j.1471-0528.2005.00609.x
PMID: 15713136.
14. McDonnell N, Knight M, Peek MJ, Ellwood D, Homer CS, McLintock C, et al. Amniotic fluid embolism:
an Australian-New Zealand population-based study. BMC Pregnancy Childbirth. 2015; 15:352. https://
doi.org/10.1186/s12884-015-0792-9 PMID: 26703453.
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